Inhalation Therapy of Calcitonin Relieves Osteoarthritis of the Knee.
10.3346/jkms.2012.27.11.1405
- Author:
Onur ARMAGAN
1
;
Dilek Kaya SERIN
;
Cuneyt CALISIR
;
Ali DOKUMACIOGLU
;
Merih OZGEN
;
Setenay ONER
;
Ozkan ALATAS
Author Information
1. Department of Physical Therapy and Rehabilitation, Eskisehir Osmangazi University Faculty of Medicine, Eskisehir, Turkey. dronurarmagan@hotmail.com
- Publication Type:Original Article ; Randomized Controlled Trial
- Keywords:
Nasal Salmon Calcitonin;
Knee Osteoarthritis;
Exercise
- MeSH:
Aged;
Bone Density Conservation Agents/*therapeutic use;
Calcitonin/*therapeutic use;
Collagen Type II/urine;
Exercise Therapy;
Female;
Humans;
Interleukin-1beta/blood;
Magnetic Resonance Imaging;
Matrix Metalloproteinase 3/blood;
Middle Aged;
Nitric Oxide/blood;
Osteoarthritis, Knee/*drug therapy/radiography;
Peptide Fragments/urine;
Respiratory Therapy;
Severity of Illness Index;
Treatment Outcome;
Walking
- From:Journal of Korean Medical Science
2012;27(11):1405-1410
- CountryRepublic of Korea
- Language:English
-
Abstract:
This study was conducted to determine if nasal salmon calcitonin has additional beneficial effects on clinical symptoms, serum NO, IL-1beta, matrix metalloproteinase 3, urinary C-terminal telopeptide type II collagen (CTX-II) levels and MRI findings in knee osteoarthritis (OA) when used concomitantly with exercise therapy. Fifty female patients with knee OA were randomized into two groups. The first group (n = 30) received 200 IU/day nasal salmon calcitonin and a home exercise program; the second group (n = 20) received a home exercise program for 6 months. Compared with baseline,while significant improvements were observed in visual analogue scale (VAS), WOMAC pain, physical function scores, 20-m walking time (P < 0.001) and WOMAC stiffness score (P = 0.041) in the first group, walking and resting VAS, and WOMAC physical function scores were improved (P = 0.029) in the second group after treatment. Significantly increased levels of serum NO and urinary CTX-II (P < 0.001) and significant improvements in the area of medial femoral condyle (P < 0.05) were noted only in the first group. There were significant differences in VAS activation values (P = 0.032) and NO levels (P < 0.001) in the favor of the first group. In conclusion, nasal salmon calcitonin may have possible chondroprotective effects besides its known effects on symptoms in patients with knee OA.
